Bild/Picture ®Thomas Ferber/Oncoletter

  • Oral Abstract Session - Pediatric Oncology I
  • Oral Abstract Session - Pediatric Oncology II
  • Poster Discussion Session - Pediatric Oncology

Oral Abstract Session - Pediatric Oncology I

High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.

Abstract: 10000: Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau Couanet, et al.

Presenter: Ruth Lydia Ladenstein MD, MBA

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.

Abstract: 10001: Selim Corbacioglu, Holger Lode, Marcus Jakob, et al.

Presenter: Selim Corbacioglu

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.

Abstract: 10002: Tara Henderson, Jenna Bardwell, Pei-Chi Kao, et al.

Presenter: Tara O. Henderson, MD, FASCO, MPH

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Biological Medicines for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG.

Abstract: 10003: Jacques Grill, Gwenael Le Teuff, Pascale Varlet, et al.

Presenter: Jacques /. Grill

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.

Abstract: 10004: Lindsay Kilburn, Dong-Anh Khuong-Quang, Karsten Nysom, et al.

Presenter: Lindsay Baker Kilburn

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Treatment of focal anaplastic Wilms tumor (FAWT): A Children’s Oncology Group (COG) report from AREN0321 and AREN03B2 studies.

Abstract: 10005: Amy Armstrong, Najat Daw, Lindsay Renfro, et al.

Presenter: Amy E. Armstrong, MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I).

Abstract: 10006: Margaret Macy, Rajen Mody, Joel Reid, et al.

Presenter: Margaret E Macy MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).

Abstract: 10007: Alice Lee, Alexander Chou, P. Williams, et al.

Presenter: Alice Lee MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

Abstract: 10008: Theodore Laetsch, Kathleen Ludwig, David Hall, et al.

Presenter: Theodore Willis Laetsch, MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session, you need an ASCO Annual Meeting registration.

-------------------------------------------------------------------------------------------------------------------------

POSTER SESSION:

Pediatric Oncology

Oral Abstract Session - Pediatric Oncology II

Feasibility of the Poverty-Targeted Pediatric Cancer Resource Equity (PediCARE) intervention.

Abstract: 10009: Haley Newman, Emily Jones, Puja Umaretiya, et al.

Presenter: Haley Newman MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Feasibility and acceptability of social determinants of health data collection in the context of a Children’s Oncology Group trial.

Abstract: 10010: Emily Jones, Arlene Naranjo, Lena Winestone, et al.

Presenter: Emily Jones, BS

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Medicaid enrollment changes among U.S. adult survivors of childhood cancer following Medicaid expansion: A report from the Childhood Cancer Survivor Study (CCSS).

Abstract: 10011: Xu Ji, Xin Hu, Ann Mertens, et al.

Presenter: Xu Ji

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Enhancing prediction of cancer therapy-related cardiomyopathy from surveillance echocardiograms: A Children’s Oncology Group (COG) report.

Abstract: 10012: Eric Chow, Kayla Stratton, Saro Armenian, et al.

Presenter: Eric Jessen Chow MD, MPH

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621.

Abstract: 10013: Saro Armenian, Melissa Hudson, Lanie Lindenfeld, et al.

Presenter: Saro Armenian

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Clonal hematopoiesis in survivors of childhood cancer.

Abstract: 10014: Danielle Friedman, Irenaeus Chan, Chaya Moskowitz, et al.

Presenter: Danielle Novetsky Friedman MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.

Abstract: 10015: Ti-Cheng Chang, Wenan Chen, Abdelrahman Elsayed, et al.

Presenter: Ti-Cheng Chang

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.

Abstract: 10016: Maureen O'Brien, Jennifer McNeer, Susan Rheingold, et al.

Presenter: Maureen Megan O'Brien, MD, MS

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).

Abstract: 10017: Edoardo Pennesi, Erica Brivio, Marieke Willemse, et al.

Presenter: Edoardo Pennesi

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

To watch the Presentation and Discussion of this Oral Abstract Session, you need an ASCO Annual Meeting registration.

--------------------------------------------------------------------------------------------------------------------------

POSTER SESSION:

Pediatric Oncology

Poster Discussion Session - Pediatric Oncology

Frequency and spectrum of clinically significant molecular alterations detected by tumor gene panel testing for pediatric cancer patients in the Texas KidsCanSeq study.

Abstract: 10018 | Poster Bd #: 324: Qing Zhou, Yi-Long Wu, Xiangqian Zheng, et al.

Presenter: Frank Y. Lin MD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.

Abstract: 10019 | Poster Bd #: 325: Pablo Berlanga, Liora Brunel, Isabelle Aerts, et al.

Presenter: Pablo Berlanga

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.

Abstract: 10020 | Poster Bd #: 326: Fernando Carceller, Harm van Tinteren, Alicia Castañeda, et al.

Presenter: Fernando Carceller

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Intensity at the end of life in pediatric neuro-oncology patients: The case for pediatric palliative care.

Abstract: 10021 | Poster Bd #: 327: Chinwe Udemgba, Karen Hoehn, Wendy Darlington, Brett Palama

Presenter: Chinwe Udemgba

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Identifying osteosarcoma signatures in cell free DNA using 5-hydroxymethylcytosine profiling.

Abstract: 10022 | Poster Bd #: 328: Evan Neczypor, Kelly Moore, Elizabeth Zeldin, et al.

Presenter: Evan William Neczypor

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A multicenter, open-label, single-arm phase 1/2 study to evaluate the safety and efficacy of FCN-159 in pediatric participants with neurofibromatosis type 1.

Abstract: 10023 | Poster Bd #: 329: Xiaojie Hu, JinHu Wang, Wenbin Li, et al.

Presenter: Xiaojie Hu

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

A phase 2 study of sirolimus in combination with metronomic chemotherapy (CHOAnome) in children with recurrent and/or refractory solid and CNS tumors.

Abstract: 10024 | Poster Bd #: 330: Thomas Cash, Dolly Aguilera, Kevin Ginn, et al.

Presenter: Thomas Cash, MD, MSc

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Physical and emotional quality of life in children with B-acute lymphoblastic leukemia randomized to every 4- vs. 12-week vincristine/dexamethasone during maintenance: Children’s Oncology Group AALL0932.

Abstract: 10025 | Poster Bd #: 331: Lyn Balsamo, John Kairalla, Emily Hibbitts, et al.

Presenter: Nina S. Kadan-Lottick, MD, MSPH

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.

Abstract: 10026 | Poster Bd #: 332: Anurekha Hall, Devan Duenas, Jenna Voutsinas, et al.

Presenter: Anurekha Gollapudi Hall, MD, MS

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

Abstract: 10027 | Poster Bd #: 333: Luciana Vinti, Stephen Daw, Constantino Sabado Alvarez, et al.

Presenter: Luciana Vinti

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Accelerated brain age and associated neurocognitive impairments in adult survivors of childhood cancer.

Abstract: 10028 | Poster Bd #: 334: Nicholas Phillips, Jessica Baedke, AnnaLynn Williams, et al.

Presenter: Nicholas Steve Phillips MD, PhD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Genetic study of type 2 diabetes risk in diverse populations of survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS).

Abstract: 10029 | Poster Bd #: 335: Cindy Im, Achal Neupane, Jessica Baedke, et al.

Presenter: Cindy Im, PhD

Zusammenfassung folgt

-------------------------------------------------------------------------------------------------------------------------

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2023. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close